The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis

• Published in: Metabolism, clinical and experimental Vol. 158; p. 155952
• Main Authors: Mercado-Gómez, Maria, Goikoetxea-Usandizaga, Naroa, Kerbert, Annarein J.C., Gracianteparaluceta, Leire Uraga, Serrano-Maciá, Marina, Lachiondo-Ortega, Sofia, Rodriguez-Agudo, Rubén, Gil-Pitarch, Clàudia, Simón, Jorge, González-Recio, Irene, Fondevila, Marcos F., Santamarina-Ojeda, Pablo, Fraga, Mario F., Nogueiras, Rubén, Heras, Javier de las, Jalan, Rajiv, Martínez-Chantar, María Luz, Delgado, Teresa C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2024
• Subjects: Ammonia; Ammonia - metabolism; Animals; Disease Progression; Fatty Liver - metabolism; Fatty Liver - pathology; Glutaminase; Glutaminase - metabolism; Hepatocytes - metabolism; Lipopolysaccharide; Lipopolysaccharides; Liver - metabolism; Liver - pathology; Male; Metabolic-associated steatotic liver disease; Mice; Mice, Inbred C57BL; Toll-like receptor 4; Toll-Like Receptor 4 - metabolism; Urea cycle; Lipopolysaccharide; Ammonia; Urea cycle; Metabolic-associated steatotic liver disease; Glutaminase; Toll-like receptor 4
• ISSN: 0026-0495; 1532-8600; 1532-8600
• DOI: 10.1016/j.metabol.2024.155952

Ammonia is a pathogenic factor implicated in the progression of metabolic-associated steatotic liver disease (MASLD). The contribution of the glutaminase 1 (GLS) isoform, an enzyme converting glutamine to glutamate and ammonia, to hepatic ammonia build-up and the mechanisms underlying its upregulation in metabolic-associated steatohepatitis (MASH) remain elusive. Multiplex transcriptomics and targeted metabolomics analysis of liver biopsies in dietary mouse models representing the whole spectra of MASLD were carried out to characterize the relevance of hepatic GLS during disease pathological progression. In addition, the acute effect of liver-specific GLS inhibition in hepatic ammonia content was evaluated in cultured hepatocytes and in in vivo mouse models of diet-induced MASLD. Finally, the regulatory mechanisms of hepatic GLS overexpression related to the lipopolysaccharide (LPS)/Toll-like receptor 4 (TLR4) axis were explored in the context of MASH. In mouse models of diet-induced MASLD, we found that augmented liver GLS expression is closely associated with the build-up of hepatic ammonia as the disease progresses from steatosis to steatohepatitis. Importantly, the acute silencing/pharmacological inhibition of GLS diminishes the ammonia burden in cultured primary mouse hepatocytes undergoing dedifferentiation, in steatotic hepatocytes, and in a mouse model of diet-induced steatohepatitis, irrespective of changes in ureagenesis and gut permeability. Under these conditions, GLS upregulation in the liver correlates positively with the hepatic expression of TLR4 that recognizes LPS. In agreement, the pharmacological inhibition of TLR4 reduces GLS and hepatic ammonia content in LPS-stimulated mouse hepatocytes and hyperammonemia animal models of endotoxemia. Overall, our results suggest that the LPS/TLR4 axis regulates hepatic GLS expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis. [Display omitted] •Accumulation of hepatic ammonia is a hallmark of steatohepatitis.•Hepatic glutaminase 1 (GLS) is increased in steatohepatitis.•Hepatic GLS expression controls hepatic ammonia accumulation in steatohepatitis.•The Lipopolysaccharide (LPS)/TLR4 axis controls hepatic GLS overexpression in steatohepatitis.